66 downloads

Novartis AG Triumphs in the Journey to Protect Vildagliptin Patent in Vietnam

Vietnam

Updated: Jul 04, 2024

2 clauses


KENFOX IP & Law Office

Verified user

KENFOX IP & Law Office

Law firm

Accepted payment methods


Key description

  • Novartis AG, a leading global pharmaceutical corporation, holds the patent for the active ingredient “Vildagliptin”, a crucial component in the treatment of type 2 diabetes. In Vietnam, this groundbreaking invention is protected under Patent No. 5529. Soon after, counterfeit products emerged in the market, significantly cheaper than the genuine product, causing confusion among consumers. Novartis

Language

Categories

Industries


Please read our Terms of service and Privacy Policy carefully before using Lexub. By using Lexub, you agree to be bound by these documents.

Write review